Lymphoma Antibodies Market Clinical Trials Report 2028

Lymphoma Antibodies Market Clinical Trials Report 2028

 

 

Global Lymphoma Antibodies market Is expected to surpass USD 5 Billion By 2028 Says Kuick Research

 

Global Lymphoma Antibodies Market and Clinical Trials Insight 2028 Report Highlights:

 

  • Global Lymphoma Antibodies Market Opportunity: >USD 5 Billion
  • Global Lymphoma Antibodies Market Insights: Current, Regional and Future Outlook 2028
  • Annual, Quarterly and Regional Sales  Insights On Lymphoma Antibodies
  • Lymphoma Antibodies Availability By Dosage, Patent, and Price Analysis
  • Clinical Insight On More Than 160 Lymphoma Antibodies In Trials
  • Lymphoma Antibodies Clinical Trials Insights by Company, Country and Phase
  • Annual, Quarterly and Regional Sales  Insights On Lymphoma Antibodies

 

The advent of antibody therapeutics represents breakthrough therapy in the management of wide range of cancers including various subtypes of lymphoma. Their strength mainly lies in their ability to activate the immune cells to specifically target the cancer cells without affecting the normal cells on the body. As of now, several monoclonal antibodies targeting different receptors such as CD20, PD-1/PD-L1, CTLA-4, and others have gained entry into the market for the management of Hodgkin lymphoma as well as non-Hodgkin lymphoma. The entrance of monoclonal antibodies has significantly improves the survival rates in these patients, thus attributing high adoption rates in the global market.

 

In addition to this, a few antibody drug conjugates have also been approved for the management of lymphoma. Antibody-drug conjugates are considered to be a new era of therapeutics. They combine the targeting ability of monoclonal antibodies with the target-specific cell-killing ability of cytotoxic drugs. The benefits associated with antibody drug conjugate have led to development of robust pipeline of these drugs which are expected to gain approval during the forecast period. For instance, Naratuximab emtansine developed by Debiopharm has demonstrated evidence of anti-tumor activity in NHL in phase-I monotherapy and successfully completed a safety lead in combination with rituximab. The product is currently in phase-IIb trial for diffuse large B-cell lymphoma. Apart from this, the investigational drug has also shown promising signs of efficacy in marginal zone lymphoma and follicular lymphoma. 

 

The progress made by science and biotechnology has led to introduction of novel technologies which enable better analysis on the progression of disease and identifies potential target which can be used for the antibody development process. For instance CD47 has been recently identified as potential therapeutic target in lymphoma. Antibodies targeting the CD47-SIRPĪ± axis have demonstrated promising results. Further, combination of CD47 inhibitory strategies and other anti-cancer therapies such as anti-CD20, anti-CD19, and others showed promising results suggesting a synergistic therapeutic effect. The forthcoming years will witness new antibody therapeutics targeting different receptors for the management of lymphoma.

 

Antibody therapeutics is among the most promising class of therapeutics which are gaining considerable interest from both large and small pharmaceutical companies. In addition, increased research activity on antibody therapy, preclinical research, increased research on late-stage drug discovery, increased research on lymphoma disorders, and increased collaboration between research institutions, biotechnology, and biopharmaceutical companies are on the market. These factors are expected to transform the overall market during the forthcoming years. The key players in the global lymphoma antibody therapeutics market include Roche, Pfizer, Ono Pharmaceutical, GlaxoSmithKline, AbbVie, ADC Therapeutics, amongst others.

 

As per our analysis, the global lymphoma antibody therapeutics market is expected to surpass US$ 5 Billion by 2028 which is mainly attributed to the increase in prevalence of lymphoma. Regionally, US hold more than 40% share in the global market which is mainly due to the rising geriatric population and high adoption to sedentary lifestyle which increase the risk of developing lymphoma. In addition, presence of major key players in the market, rising government initiatives, and favorable reimbursement policies are the other factors which are driving the growth of the market in the region.

 

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry. In addition, commercial information including price, patent, dosage and sales analysis of already approved antibody therapeutics in the market is also mentioned in the report.

Back to news